MedPath
Found 27 clinical trials|View Analysis
Sort by:

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Phase 2
Recruiting
Conditions
Brain Tumor, Primary
CNS Cancer
Brain Metastases
Brain Neoplasms
Multiple Sclerosis
Acoustic Neuroma
CNS Lesion
CNS Metastases
Central Nervous System (CNS) Lesions
Neurofibroma
Interventions
Drug: RVP-001
First Posted Date
2024-03-21
Last Posted Date
2024-10-07
Lead Sponsor
Reveal Pharmaceuticals Inc.
Target Recruit Count
24
Registration Number
NCT06322342
Locations
🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients

Not Applicable
Recruiting
Conditions
Exercise
Brain Tumor, Primary
Interventions
Other: High-Intensity Interval Training (HIIT)
First Posted Date
2024-02-28
Last Posted Date
2024-03-06
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
36
Registration Number
NCT06282562
Locations
🇳🇱

VU University Medical Centers, location VUmc, Amsterdam, Netherlands

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

Recruiting
Conditions
Brain Tumor, Primary
Interventions
Other: Cognitive testing
Device: Resting State MRI/Precision functional mapping
First Posted Date
2023-12-29
Last Posted Date
2024-07-12
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
16
Registration Number
NCT06185686
Locations
🇺🇸

Washington University School of Medicine/Saint Louis Children's Hospital, Saint Louis, Missouri, United States

Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow

Not Applicable
Not yet recruiting
Conditions
Brain Tumor, Primary
Brain Tumor - Metastatic
Interventions
Radiation: brain radiotherapy
First Posted Date
2023-10-30
Last Posted Date
2023-10-30
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
54
Registration Number
NCT06106997
Locations
🇩🇪

Erlangen, Universitätsklinikum Strahlenklinik, Erlangen, Germany

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

Phase 3
Recruiting
Conditions
Brain Tumor, Recurrent
Brain Tumor, Primary
Interventions
First Posted Date
2023-09-28
Last Posted Date
2024-05-03
Lead Sponsor
Guerbet
Target Recruit Count
138
Registration Number
NCT06057168
Locations
🇮🇹

Policlinico Universitario Agostino Gemelli, Roma, Italy

🇵🇱

Szpital Specjalistyczny im.L.Rydygiera, Kraków, Poland

🇮🇹

Ospedale Papa Giovanni XXIII, Bergamo, Italy

and more 8 locations

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Recruiting
Conditions
Brain Tumor - Metastatic
Brain Tumor, Primary
Interventions
Diagnostic Test: Circulating leukocytes immunophenotype
Diagnostic Test: Tumor sampling
First Posted Date
2023-04-26
Last Posted Date
2023-04-26
Lead Sponsor
Pietro Mortini, MD, Prof.
Target Recruit Count
200
Registration Number
NCT05831631
Locations
🇮🇹

IRCCS San Raffaele Scientific Institute, Milan, Italy

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Recruiting
Conditions
Brain Tumor, Primary
Interventions
Diagnostic Test: Blood, CSF and tumor samples
First Posted Date
2023-03-20
Last Posted Date
2024-01-23
Lead Sponsor
IRCCS San Raffaele
Target Recruit Count
50
Registration Number
NCT05775458
Locations
🇮🇹

IRCCS San Raffaele Scientific Institute, Milan, Italy

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Recruiting
Conditions
Brain Metastases, Adult
Brain Tumor, Primary
First Posted Date
2022-07-29
Last Posted Date
2025-01-07
Lead Sponsor
Duke University
Target Recruit Count
300
Registration Number
NCT05480644
Locations
🇺🇸

Duke Cancer Center, Durham, North Carolina, United States

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

Recruiting
Conditions
Brain Tumor, Primary
Schwannoma
Meningioma
Gliomas Benign
Pituitary Adenoma
First Posted Date
2022-02-24
Last Posted Date
2024-12-03
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
3000
Registration Number
NCT05254197
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Phase 2
Conditions
Brain Tumor, Primary
Interventions
Drug: HLX208
First Posted Date
2021-10-26
Last Posted Date
2022-05-03
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
40
Registration Number
NCT05092802
Locations
🇨🇳

Cancer Hospital Affiliated to Shandong first medical University, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath